The development of treatments based on genetic mutations such as PARPis for HRR gene mutations, AKT inhibitors for patients with genetic mutations in the PI3K/Akt pathway, and ICI for mutations in MMR genes and cases of MSI-high or high-tumor-mutational-burden CSPC and CRPC is anticipated. Here, AKT1 is linked to neoplasm.